Multiple Myeloma Articles

Proteasome Inhibitors Paving Promising Path for Myeloma Treatment
Kenneth H. Shain, MD, discusses the emergence of proteasome inhibitors in multiple myeloma and whether these agents will be best used as monotherapy or in combination regimens.
Myeloma Trial Explores Optimal Induction, Maintenance Regimens
Two combination regimens anchored by different proteasome inhibitors are being compared in a national clinical trial for patients with newly diagnosed symptomatic multiple myeloma that also seeks to evaluate the ideal duration of lenalidomide (Revlimid) maintenance therapy.
Amgen has announced that it has submitted supplemental New Drug Applications (sNDA) in the United States and Europe based on data from 2 phase III studies showing carfilzomib (Kyprolis) improves overall survival (OS) for patients with relapsed/refractory multiple myeloma.
Carfilzomib Combo Extends Survival for Myeloma in Final ASPIRE Analysis
The combination of carfilzomib (Kyprolis), lenalidomide (Revlimid), and dexamethasone reduced the risk of death by 21% compared with lenalidomide and dexamethasone alone for patients with relapsed multiple myeloma.
FDA Places Clinical Hold on 3 Pembrolizumab Myeloma Trials
The FDA has placed a clinical hold on the phase III KEYNOTE-183 and KEYNOTE-185 pembrolizumab (Keytruda) trials and ordered the discontinuation of the lenalidomide/dexamethasone/pembrolizumab arm of the KEYNOTE-023 trial in patients with multiple myeloma.
Comparison of Induction Therapies Prior to ASCT Favors Novel Quadruple Over Triplet Regimens
Results from the phase III Myeloma XI study showed that patients with myeloma had deeper responses after induction and after allo-stem cell transplantation with outpatient-delivered quadruplet therapy than with sequential immunomodulatory triplet combinations.
Ixazomib Maintenance Shows Robust Activity in Multiple Myeloma
Patients with newly-diagnosed multiple myeloma who did not elect to undergo stem cell transplant but remained on single agent ixazomib maintenance fared as well as those who received SCT.
Response Rate Hits 100% for bb2121 in Multiple Myeloma
All patients with multiple myeloma in a phase I study showed a response following treatment with an active dose of bb2121, an investigational anti–BCMA CAR T-cell construct.
FDA Accepts Denosumab sBLA for Multiple Myeloma
The FDA has accepted a supplemental biologics license application for the use of denosumab (Xgeva) for the prevention of skeletal-related events in patients with multiple myeloma.
FDA Approves Third Daratumumab Triplet for Myeloma
The FDA has approved daratumumab for use in combination with pomalidomide and dexamethasone for patients with multiple myeloma who have received at least 2 prior therapies, including a proteasome inhibitor and lenalidomide.
Publication Bottom Border
Border Publication